BioSpace News Archive

The National Kidney Foundation is proud to announce the appointment of Lynn Pina, Chief Marketing Officer of GeoBlue, to its National Board of Directors.

Precision BioSciences, Inc. announced that, on November 2, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.

Regeneron Pharmaceuticals, Inc. announced late-breaking presentations of updated results from two positive pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® Injection, in patients with diabetic macular edema and wet age-related macular degeneration.

IVERIC bio, Inc. announced that Iveric Bio management will participate in fireside chats at the following investor conferences in November.

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced its participation in the upcoming investor conferences.

Regulatory News: Innate Pharma SA announced that the following presentations will be presented at the 64th ASH Annual Meeting taking place from December 10-13, 2022, in New Orleans, Louisiana.

The European Commission has approved Beyfortus® for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants during their first RSV season.

NeoImmuneTech, Inc. announced it will present first data from the combination of its main asset, NT-I7, with the chimeric antigen receptor T-cell tisagenlecleucel, at the American Society of Hematology annual meeting, to be held in New Orleans, Louisiana, December 10-13, 2022.

Cynata Therapeutics Limited is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata’s Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.

Syneos Health, the only fully integrated biopharmaceutical solutions organization, reported financial results for the three and nine months ended September 30, 2022.